Zealand Pharma A/S Stock Forecast, Price & News

Zealand Pharma A/S (NASDAQ:ZEAL) Frequently Asked Questions

Is Zealand Pharma A/S a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zealand Pharma A/S in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zealand Pharma A/S stock.
View analyst ratings for Zealand Pharma A/S or view top-rated stocks.

How has Zealand Pharma A/S's stock been impacted by COVID-19 (Coronavirus)?

Zealand Pharma A/S's stock was trading at $28.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ZEAL stock has decreased by 33.4% and is now trading at $18.7079.
View which stocks have been most impacted by COVID-19.

Are investors shorting Zealand Pharma A/S?

Zealand Pharma A/S saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 165,800 shares, an increase of 24.5% from the December 15th total of 133,200 shares. Based on an average trading volume of 5,200 shares, the short-interest ratio is presently 31.9 days.
View Zealand Pharma A/S's Short Interest.

When is Zealand Pharma A/S's next earnings date?

Zealand Pharma A/S is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Zealand Pharma A/S.

How were Zealand Pharma A/S's earnings last quarter?

Zealand Pharma A/S (NASDAQ:ZEAL) issued its earnings results on Wednesday, November, 10th. The company reported ($4.61) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($6.31) by $1.70. The firm earned $16.87 million during the quarter, compared to the consensus estimate of $12.21 million. Zealand Pharma A/S had a negative trailing twelve-month return on equity of 82.62% and a negative net margin of 371.32%. During the same quarter last year, the company earned ($0.90) EPS.
View Zealand Pharma A/S's earnings history.

Who are Zealand Pharma A/S's key executives?

Zealand Pharma A/S's management team includes the following people:

• Emmanuel Dulac, President & Chief Executive Officer
• Ivan M. Møller, Senior VP-Technical Development & Operations
• Matthew D. Dallas, Chief Financial Officer & Senior Vice President
• Adam Sinding Steensberg, Chief Medical Officer, EVP-Research & Development
• Danilo Verge, Head-Global Medical Affairs

Who are some of Zealand Pharma A/S's key competitors?

Some companies that are related to Zealand Pharma A/S include Apellis Pharmaceuticals (APLS), CureVac (CVAC), Karuna Therapeutics (KRTX), Dicerna Pharmaceuticals (DRNA), Prestige Consumer Healthcare (PBH), Pacira BioSciences (PCRX), PTC Therapeutics (PTCT), Cytokinetics (CYTK), Amicus Therapeutics (FOLD), Insmed (INSM), Emergent BioSolutions (EBS), Zentalis Pharmaceuticals (ZNTL), Sage Therapeutics (SAGE), Indivior (INVVY) and Nuvation Bio (NUVB).
View all of ZEAL's competitors.

What other stocks do shareholders of Zealand Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zealand Pharma A/S investors own include AbbVie (ABBV), Galapagos (GLPG), Verizon Communications (VZ), Dynavax Technologies (DVAX), EyePoint Pharmaceuticals (EYPT), Progenics Pharmaceuticals (PGNX), Protalix BioTherapeutics (PLX), Portola Pharmaceuticals (PTLA), Sangamo Therapeutics (SGMO) and Sorrento Therapeutics (SRNE).

When did Zealand Pharma A/S IPO?

(ZEAL) raised $75 million in an IPO on Wednesday, August 9th 2017. The company issued 3,900,000 shares at $19.30 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

What is Zealand Pharma A/S's stock symbol?

Zealand Pharma A/S trades on the NASDAQ under the ticker symbol "ZEAL."

How do I buy shares of Zealand Pharma A/S?

Shares of ZEAL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zealand Pharma A/S's stock price today?

One share of ZEAL stock can currently be purchased for approximately $18.71.

How much money does Zealand Pharma A/S make?

Zealand Pharma A/S has a market capitalization of $816.30 million and generates $54.13 million in revenue each year. The company earns $-129.72 million in net income (profit) each year or ($4.34) on an earnings per share basis.

How many employees does Zealand Pharma A/S have?

Zealand Pharma A/S employs 329 workers across the globe.

What is Zealand Pharma A/S's official website?

The official website for Zealand Pharma A/S is www.zealandpharma.com.

Where are Zealand Pharma A/S's headquarters?

Zealand Pharma A/S is headquartered at SYDMARKEN 11, COPENHAGEN G7, 2860.

How can I contact Zealand Pharma A/S?

Zealand Pharma A/S's mailing address is SYDMARKEN 11, COPENHAGEN G7, 2860. The company can be reached via phone at (458) 877-3600, via email at [email protected], or via fax at 45-8877-3898.